Research / Stocks / HAE HAE NYSE CIK 0000313143
HAEMONETICS CORP · Surgical & Medical Instruments & Apparatus
COVERAGE / STANDARD
Latest filing 8-K · Aug 18, 2026
Research state Latest filing analysis is current
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Research Current Validated structured financial research is available
Filing Analysis Research Current No filing analysis job is currently running
Fundamental State Research Current Fundamental State depends on validated comparable financial metrics
RESEARCH SNAPSHOT HAEMONETICS CORP's latest supported as-filed period reports revenue of $339.4M ; gross margin moved 6 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
Deterministic / evidence backed Key research observations No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Current configuration / point in time Fundamental state A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Debt relative to revenue 33th Own-history percentile · N=9
Method Level · gp.fundamentals.debt_to_revenue
Raw value 350.11% · OPTIONAL
Capex intensity 44th Own-history percentile · N=9
Method Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.33% · OPTIONAL
Operating cash generation 67th Own-history percentile · N=9
Method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 15.42% · OPTIONAL
Revenue growth RAW Current state valid · history insufficient
Method Yoy · gp.fundamentals.revenue
Raw value 5.60% · CORE
Inventory pressure 33th Own-history percentile · N=9
Method Level · gp.fundamentals.inventory_revenue_ratio
Raw value 90.38% · OPTIONAL
Gross margin 89th Own-history percentile · N=9
Method Level · gp.fundamentals.gross_margin
Raw value 59.76% · CORE
Operating margin 67th Own-history percentile · N=9
Method Level · gp.fundamentals.operating_margin
Deterministic multi-period research Company direction Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
As filed Jun 27, 2026 General Corporate
Capital Allocation 5 evidence-backed dimensions Balance Sheet Leverage Inflecting Capex Intensity Inflecting Cash Generation Improving R And D Intensity Inflecting Sbc Intensity Stable [email protected] · 10 historical states · 38% confidenceCompany Direction 9 evidence-backed dimensions Balance Sheet Leverage Inflecting Capex Intensity Inflecting Cash Generation Improving Inventory Pressure Improving Margin Stable [email protected] · 10 historical states · 36% confidenceFinancial Quality 6 evidence-backed dimensions Balance Sheet Leverage Inflecting Cash Generation Improving Inventory Pressure Improving Margin Stable Profitability Stable [email protected] · 10 historical states · 38% confidenceGovernance Evidence 4 evidence-backed dimensions Filing Amendments None Detected Auditor Changes None Detected Sbc Intensity Observed Insider Activity Observed [email protected] · 10 historical states · 50% confidence
Comparable evidence Peer context Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
Cash Generation
HAE 15.4
Peer median -10.1
Peer percentile 88th 81 valid peers · 92% coverage · +0.7 robust σ Profitability
HAE 16.9
Peer median -6.7
Peer percentile 88th 83 valid peers · 94% coverage · +0.7 robust σ Inventory Pressure
HAE 90.4
Peer median 72.0
Peer percentile 73th 79 valid peers · 90% coverage · +0.6 robust σ R And D Intensity
HAE 4.8
Peer median 13.2
Peer percentile 24th 68 valid peers · 77% coverage · -0.6 robust σ Sbc Intensity
HAE 2.7
Peer median 5.9
Peer percentile 31th 81 valid peers · 92% coverage · -0.5 robust σ Margin
HAE 59.8
Peer median 64.6
Peer percentile 41th 76 valid peers · 86% coverage · -0.3 robust σ Open group breadth → Divergence is context, not positive or negative. INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0000313143-26-000120 16 governed changes · top 7 shown
01
MEDIUM IMPORTANCE Capex 100TH HISTORICAL PCTL · N=2
Capex / revenue moved 116 bp higher Capex / revenue changed +116 basis points from the comparable as-filed period.
Why this ranks here · [email protected] 1.17% → 2.33% Comparable → current
02
HIGH IMPORTANCE Capex 100TH HISTORICAL PCTL · N=6
Capital expenditure increased 110.6% Capital expenditure changed +110.6% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes.
Why this ranks here · [email protected] $3.8M → $7.9M Comparable → current
03
HIGH IMPORTANCE Cash 50TH HISTORICAL PCTL · N=2
Cash & equivalents decreased 23.7% Cash & equivalents changed -23.7% from the comparable as-filed period.
Why this ranks here · [email protected] $292.9M → $223.4M Comparable → current
04
INFORMATIONAL IMPORTANCE Debt 33TH HISTORICAL PCTL · N=3
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 2.33% +0.0% ↑ Capital expenditure $7.9M -75.9% ↓ Cash & equivalents $223.4M +0.0% ↑ Debt $1.2B +23593.0% ↑ Free-cash-flow proxy $44.4M +0.0% ↑ Gross margin 59.76% +0.0% ↑ Interest expense $106,000 +1666.7% ↑ Inventory $306.7M +0.1% ↑
ACTIVE TRACE Revenue HAE · as filed with the SEC · reported-date aware
Capex / revenue Q1 / 2026-06-27 2.33% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q1 / 2026-06-27 $7.9M -75.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q1 / 2026-06-27 $223.4M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Debt Q1 / 2026-06-27 $1.2B +23593.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q1 / 2026-06-27 $44.4M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin Q1 / 2026-06-27 59.76% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense Q1 / 2011-07-02 $106,000 +1666.7% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory Q1 / 2026-06-27 $306.7M +0.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Net income Q1 / 2026-06-27 $33.0M -66.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q1 / 2026-06-27 $52.3M -82.2% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q1 / 2026-06-27 16.93% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q1 / 2026-06-27 $16.2M -72.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
8-K Aug 18, 2026 Period Aug 18, 2026 0000313143-26-000135SEC ↗ 10-Q Aug 6, 2026 Period Jun 27, 2026 0000313143-26-000120SEC ↗ 8-K Aug 6, 2026 Period Aug 6, 2026 0000313143-26-000118SEC ↗ 4 Jul 28, 2026 Period Jul 24, 2026 0000313143-26-000112SEC ↗ 4 Jul 28, 2026 Period Jul 24, 2026 0000313143-26-000111SEC ↗ 4 Jul 28, 2026 Period Jul 24, 2026 0000313143-26-000109SEC ↗ 4 Jul 28, 2026 Period Jul 24, 2026 0000313143-26-000107SEC ↗ 4 Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗